… These relapses are caused by the persistent leukemic blasts … Citation40 Achievement of
complete molecular remission (… Standardisation and consensus guidelines for minimal residual …

… complete remission. However, up to half of patients have persistent minimal/measurable
residual … kinase inhibitor (TKI) and achieved a complete molecular response (CMR; defined as …

… or biopsies, cytogenetic analyses, and molecular testing using … dynamics, and the persistent
molecular MRD status in the … was associated with a conventional remission status, and the …

… : BM in complete remission can contain leukemic … molecular genetics and MRD data were
integrated into a single combined classification to refine treatment stratification in the ongoing …

… In the meantime, to ensure continued support, we are … neg CR or CR with incomplete
hematologic recovery (CRi) and were … Moreover, information on molecular and FISH testing was …

… Molecular relapse has also been noted to precede hematologic relapse by about 2.6 months…
proceeded to alloHSCT in continuous complete remission after blinatumomab were alive, …

… complete remission (CR)/CR with incomplete hematologic … A final intriguing outcome is our
observation that continued B-… Further study of this population, including detailed molecular …

Background The presence of minimal residual disease (MRD) is an independent risk factor
for poor prognosis in patients with acute lymphoblastic leukemia (ALL). Moreover, the role of …

… complete remission (CR1) but with persistent measurable … Patients who did not reach
hematologic CR after 2 cycles of … patients achieved sustained minimal residual disease negativity. …

… -established in hematologic malignancies with … Persistent molecular disease continued
for a median of 1.5 years and up to a maximum of 3.4 years from the time of complete remission…